Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim resultsSham Mailankody, Shaji Kumar, Shahbaz A. Malik et al.|Nature Medicine|2023Cited by 239
JCARH125, Anti-BCMA CAR T-cell Therapy for Relapsed/Refractory Multiple Myeloma: Initial Proof of Concept Results from a Phase 1/2 Multicenter Study (EVOLVE)Sham Mailankody, Andrzej Jakubowiak, Myo Htut et al.|Blood|2018Cited by 124
Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011).Sham Mailankody, Sandy W. Wong, Andrzej Jakubowiak et al.|Journal of Clinical Oncology|2020Cited by 122